CTX-112 is under clinical development by CRISPR Therapeutics and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II drugs for Follicular Lymphoma have a 43% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CTX-112’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CTX-112 overview
CTX-112 is under development for the treatment of relapsed and refractory B-cell malignancies including non-Hodgkin lymphoma, chronic lymphocytic leukemia, small lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma and systemic lupus erythematosus (SLE). The therapeutic candidate (CAR-T) comprises of genetically modified allogeneic T cells expressing chimeric antigen receptors targeting cells expressing B lymphocyte antigen CD19. It is administered through intravenous route and is being developed based on CRISPR's gene-editing technology.
CRISPR Therapeutics overview
CRISPR Therapeutics is a gene editing company. It utilizes its proprietary technology, CRISPR (Clustered, Regularly Interspaced Short Palindromic Repeats)/Cas9 (CRISPR-associated protein-9), to precisely alter specific sequences of genomic deoxyribonucleic acid (DNA). The company’s products are primarily used in the healthcare industry, specifically in the treatment and prevention of both rare and common diseases. Its portfolio includes multiple therapeutic programs in areas such as hemoglobinopathies, immuno-oncology, autoimmune diseases, and type 1 diabetes. The company’s advanced program, Casgevy, is approved for treating severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). CRISPR Therapeutics is headquartered in Zug, Switzerland.
For a complete picture of CTX-112’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
